Medannex Advances First ANAX1 Antagonist With Modular Cancer Trial Approach
Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.
You may also be interested in...
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.
The US firm is touting top-line data from an open-label Alzheimer’s disease trial as a net positive, but the lack of p-values and a declining trend in efficacy left some investors and analysts lukewarm.